earnings
confidence high
sentiment positive
materiality 0.75
Novocure Q1 net revenue $174M (+12% YoY); raises FY2026 guidance; Optune Pax launch
NovoCure Ltd
2026-Q1 EPS reported
-$0.62
revenue$174,055,000
- Net loss of $71.1M ($0.62 per share); Adjusted EBITDA of -$0.3M.
- Gross margin improved to 78% (from 75%) on lower array costs.
- Optune Pax FDA approved for locally advanced pancreatic cancer; 169 prescriptions, 83 active patients as of March 31, 2026.
- FY2026 revenue guidance raised to $690M-$710M (from $675M-$705M); Adj. EBITDA guidance narrowed to -$15M-$0M.
- PANOVA-4 Phase 2 met primary endpoint with 74% disease control rate vs 48% historical control.
item 2.02item 9.01